Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis

Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review

(2018) Domenico Plantone et al.   CLINICAL DRUG INVESTIGATION

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

(2017) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Arthritis after cancer immunotherapy: symptom duration and treatment response

(2017) Melanie H. Smith et al.   ARTHRITIS CARE & RESEARCH

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

(2017) Laura C. Cappelli et al.   ARTHRITIS CARE & RESEARCH

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

(2016) Laura C Cappelli et al.   ANNALS OF THE RHEUMATIC DISEASES

Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies

(2016) Steve Pascolo   EUROPEAN JOURNAL OF PHARMACOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort

(2012) R Willis et al.   LUPUS

Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines

(2011) A. Kuznik et al.   JOURNAL OF IMMUNOLOGY